Pilot Study in Canine Elbow OA

A pilot study assesses the efficacy of 2.5% PAAG in 20 Labrador Retrievers with Elbow Dysplasia (2017-2018)

Background: 20 Labrador Retriever dogs with moderate to severe elbow dysplasia and osteoarthritis (OA) who were clinically lame were enrolled into the pilot study after undergoing veterinary diagnostic imaging. This included radiography, computed tomography and arthroscopy.

Treatment: 1ml of 2.5% PAAG was injected into the worst elbow joint via intra-articular injection. Response to the treatment was evaluated by Gait4Dog gait analysis, HALO goniometry, AimOA and clinical findings.

Outcome: 2.5% PAAG significantly improved the lameness during the first 4 weeks after treatment in 75% of patients (P<0.05). Elbow flexion (P=0.04), pain parameters (P=0.002) and limb function (P=0.001) also significantly improved. Gait analysis showed a significant improvement in weight bearing pressure between baseline and week 4 (P=0.007).

Study Limitations: Several limitations arose which need to be addressed in future studies. Variables such as age range, grades of OA, degree of lameness, exercise levels, diet and weight loss during the study period should be controlled. Longer multi-centred studies with randomization, double blinding and suitable controls are essential and are being commissioned in Europe at present.

Conclusion: The major finding of the pilot study is that 2.5% PAAG significantly improved lameness, function and pain parameters indicating effective symptomatic treatment of osteoarthritis associated with elbow dysplasia in dogs. Further studies that maximise data obtainable from joints treated with 2.5% PAAG will continue to build on the mounting evidence that AV is a novel treatment option for OA in animals.

Arthramid Vet 2.5% PAAG

Precision Medicine

  • Studies show up to 82.5% of horses respond with a successful resolution of joint lameness.
  • Meets Animal Welfare Concerns; Arthramid Vet is not simply a lubricant or painkiller. Its unique biomedical technology that helps heal and restore the joint to healthy function.
  • Made to Last; When compared to traditional treatments for joint lameness, research shows that Arthramid Vet is better and lasts longer with proven efficacy for up to 1- 2 years.
  • One of A Kind; Arthramid Vet's unique and patented IL-X Cross-Linking technology makes it the safest and most effective 2.5% Polyacrylamide (PAAG) Hydrogel available.
  • Addresses Equine Welfare Concerns
  • Long-lasting Clinical Effects of Treatment
  • 82.5% Successful Resolution of Joint Lameness

Get In Touch

Contact Us

First Name:
Last Name:
Your Email:
Phone:
Business Name:
Subject:

IMS Vet
Phone +64 (09) 8013 253
sales@imsvet.com

Arthramid Vet Australia

Registered in Australia to: IMS Vet Pty Limited, 1953 Grampian's Road, Fyans Creek, Victoria 3381. Registered pursuant to the APVMA Number 86728/0320. See www.apvma.gov.au for registration conditions.

Address for Service:
IMSVet, PO Box 1083, Cambridge 3450, New Zealand
Phone +61 (0272) 018 497
sales@imsvet.com